206 related articles for article (PubMed ID: 21934682)
1. Src homology domain-containing phosphatase 2 suppresses cellular senescence in glioblastoma.
Sturla LM; Zinn PO; Ng K; Nitta M; Kozono D; Chen CC; Kasper EM
Br J Cancer; 2011 Oct; 105(8):1235-43. PubMed ID: 21934682
[TBL] [Abstract][Full Text] [Related]
2. Data-Driven Computational Modeling Identifies Determinants of Glioblastoma Response to SHP2 Inhibition.
Day EK; Zhong Q; Purow B; Lazzara MJ
Cancer Res; 2021 Apr; 81(8):2056-2070. PubMed ID: 33574084
[TBL] [Abstract][Full Text] [Related]
3. Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature.
Jones KA; Gilder AS; Lam MS; Du N; Banki MA; Merati A; Pizzo DP; VandenBerg SR; Gonias SL
Neuro Oncol; 2016 May; 18(5):667-78. PubMed ID: 26420897
[TBL] [Abstract][Full Text] [Related]
4. Protein Tyrosine Phosphatase SHP2 Suppresses Host Innate Immunity against Influenza A Virus by Regulating EGFR-Mediated Signaling.
Wang Q; Pan W; Wang S; Pan C; Ning H; Huang S; Chiu SH; Chen JL
J Virol; 2021 Feb; 95(6):. PubMed ID: 33361428
[TBL] [Abstract][Full Text] [Related]
5. Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells.
Furcht CM; Buonato JM; Skuli N; Mathew LK; Muñoz Rojas AR; Simon MC; Lazzara MJ
J Cell Sci; 2014 Aug; 127(Pt 16):3555-67. PubMed ID: 24951116
[TBL] [Abstract][Full Text] [Related]
6. LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt/GSK-3β/β-catenin signaling.
Ishida H; Kogaki S; Narita J; Ichimori H; Nawa N; Okada Y; Takahashi K; Ozono K
Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1531-9. PubMed ID: 21803945
[TBL] [Abstract][Full Text] [Related]
7. SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells.
Leibowitz MS; Srivastava RM; Andrade Filho PA; Egloff AM; Wang L; Seethala RR; Ferrone S; Ferris RL
Clin Cancer Res; 2013 Feb; 19(4):798-808. PubMed ID: 23363816
[TBL] [Abstract][Full Text] [Related]
8. Ethacrynic acid inhibits STAT3 activity through the modulation of SHP2 and PTP1B tyrosine phosphatases in DU145 prostate carcinoma cells.
Lee YJ; Song H; Yoon YJ; Park SJ; Kim SY; Cho Han D; Kwon BM
Biochem Pharmacol; 2020 May; 175():113920. PubMed ID: 32201212
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by signal-regulatory proteins (SIRPs).
Wu CJ; Chen Z; Ullrich A; Greene MI; O'Rourke DM
Oncogene; 2000 Aug; 19(35):3999-4010. PubMed ID: 10962556
[TBL] [Abstract][Full Text] [Related]
10. Shp2 Inhibits Proliferation of Esophageal Squamous Cell Cancer via Dephosphorylation of Stat3.
Qi C; Han T; Tang H; Huang K; Min J; Li J; Ding X; Xu Z
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28085101
[TBL] [Abstract][Full Text] [Related]
11. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
Fragale A; Tartaglia M; Wu J; Gelb BD
Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
[TBL] [Abstract][Full Text] [Related]
12. Regulation of neuregulin-mediated acetylcholine receptor synthesis by protein tyrosine phosphatase SHP2.
Tanowitz M; Si J; Yu DH; Feng GS; Mei L
J Neurosci; 1999 Nov; 19(21):9426-35. PubMed ID: 10531446
[TBL] [Abstract][Full Text] [Related]
13. Negative regulation of gp130 signalling mediated through tyrosine-757 is not dependent on the recruitment of SHP2.
Fairlie WD; De Souza D; Nicola NA; Baca M
Biochem J; 2003 Jun; 372(Pt 2):495-502. PubMed ID: 12593670
[TBL] [Abstract][Full Text] [Related]
14. A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2).
Hartman Z; Geldenhuys WJ; Agazie YM
J Biol Chem; 2020 Mar; 295(11):3563-3575. PubMed ID: 32024694
[TBL] [Abstract][Full Text] [Related]
15. Small-Molecule Inhibitors of Shp2 Phosphatase as Potential Chemotherapeutic Agents for Glioblastoma: A Minireview.
Mitra R; Ayyannan SR
ChemMedChem; 2021 Mar; 16(5):777-787. PubMed ID: 33210828
[TBL] [Abstract][Full Text] [Related]
16. T cell-specific constitutive active SHP2 enhances T cell memory formation and reduces T cell activation.
Cammann C; Israel N; Frentzel S; Jeron A; Topfstedt E; Schüler T; Simeoni L; Zenker M; Fehling HJ; Schraven B; Bruder D; Seifert U
Front Immunol; 2022; 13():958616. PubMed ID: 35983034
[TBL] [Abstract][Full Text] [Related]
17. SHP2 regulates proliferation and tumorigenicity of glioma stem cells.
Roccograndi L; Binder ZA; Zhang L; Aceto N; Zhang Z; Bentires-Alj M; Nakano I; Dahmane N; O'Rourke DM
J Neurooncol; 2017 Dec; 135(3):487-496. PubMed ID: 28852935
[TBL] [Abstract][Full Text] [Related]
18. TNF-alpha induces tyrosine phosphorylation and recruitment of the Src homology protein-tyrosine phosphatase 2 to the gp130 signal-transducing subunit of the IL-6 receptor complex.
Bode JG; Schweigart J; Kehrmann J; Ehlting C; Schaper F; Heinrich PC; Häussinger D
J Immunol; 2003 Jul; 171(1):257-66. PubMed ID: 12817006
[TBL] [Abstract][Full Text] [Related]
19. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).
Zhang X; He Y; Liu S; Yu Z; Jiang ZX; Yang Z; Dong Y; Nabinger SC; Wu L; Gunawan AM; Wang L; Chan RJ; Zhang ZY
J Med Chem; 2010 Mar; 53(6):2482-93. PubMed ID: 20170098
[TBL] [Abstract][Full Text] [Related]
20. SH2 domain-containing phosphatase-2 protein-tyrosine phosphatase promotes Fc epsilon RI-induced activation of Fyn and Erk pathways leading to TNF alpha release from bone marrow-derived mast cells.
McPherson VA; Sharma N; Everingham S; Smith J; Zhu HH; Feng GS; Craig AW
J Immunol; 2009 Oct; 183(8):4940-7. PubMed ID: 19786542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
